Association of the time of trastuzumab exposition with outcome in breast cancer patients

Published: 22 November 2021| Version 2 | DOI: 10.17632/t3yb6fy69b.2
Contributors:
Felipe Andrés Cordero da Luz,
,
,
,
,
,
,

Description

Shorter times of trastuzumab exposition (<1 year) could protect from disease progression in breast cancer patients. Survival analysis of continuous predictor was used to obtain optimal cut-offs regarding DMFS, DFS, and OS.

Files

Categories

Breast Cancer

License